Sun Pharma Q2 Sales Rise 11.8% To ₹16,100 Crore; India Grows 17.3%, US Sales Decline 8.2%

Sun Pharmaceutical Industries reported 11.8% year-on-year growth in sales to ₹16,100 crore in Q2 FY27. Adjusted net profit stood at ₹3,162 crore, while reported net profit was ₹1,988.5 crore. EBITDA increased 4.8% to ₹4,743.9 crore, with an EBITDA margin of 29.3%. India formulations sales grew 17.3% to ₹5,552.3 crore, while US formulations sales declined 8.2% to $455 million. Global innovative medicines sales rose 6.9% to $356 million. The company also said regulatory approvals for its proposed Organon acquisition had been secured in most regions. Business Today TV speaks to Jayashree Satagopan, Chief Financial Officer, Sun Pharmaceutical Industries, on quarterly performance, market growth, margins, R&D investments and the Organon acquisition.